|
1
|
Vincent A, Herman J, Schulick R, Hruban RH
and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Saif MW: Advanced stage pancreatic cancer:
Novel therapeutic options. Expert Rev Clin Pharmacol. 7:487–498.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cid-Arregui A and Juarez V: Perspectives
in the treatment of pancreatic adenocarcinoma. World J
Gastroenterol. 21:9297–9316. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardière C, et al: Groupe Tumeurs Digestives of Unicancer;
PRODIGE Intergroup: FOLFIRINOX versus gemcitabine for metastatic
pancreatic cancer. N Engl J Med. 364:1817–1825. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang Z, Inuzuka H, Zhong J, Wan L,
Fukushima H, Sarkar FH and Wei W: Tumor suppressor functions of
FBW7 in cancer development and progression. FEBS Lett.
586:1409–1418. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Min SH, Lau AW, Lee TH, Inuzuka H, Wei S,
Huang P, Shaik S, Lee DY, Finn G, Balastik M, et al: Negative
regulation of the stability and tumor suppressor function of Fbw7
by the Pin1 prolyl isomerase. Mol Cell. 46:771–783. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Akhoondi S, Sun D, von der Lehr N,
Apostolidou S, Klotz K, Maljukova A, Cepeda D, Fiegl H, Dafou D,
Marth C, et al: FBXW7/hCDC4 is a general tumor suppressor in
human cancer. Cancer Res. 67:9006–9012. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Akhoondi S, Lindström L, Widschwendter M,
Corcoran M, Bergh J, Spruck C, Grandér D and Sangfelt O:
Inactivation of FBXW7/hCDC4-β expression by promoter
hypermethylation is associated with favorable prognosis in primary
breast cancer. Breast Cancer Res. 12:R1052010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ji S, Qin Y, Shi S, Liu X, Hu H, Zhou H,
Gao J, Zhang B, Xu W, Liu J, et al: ERK kinase phosphorylates and
destabilizes the tumor suppressor FBW7 in pancreatic cancer. Cell
Res. 25:561–573. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ji S, Qin Y, Liang C, Huang R, Shi S, Liu
J, Jin K, Liang D, Xu W, Zhang B, et al: FBW7 (F-box and WD repeat
domain- containing 7) negatively regulates glucose metabolism by
targeting the c-Myc/TXNIP (thioredoxin-binding protein) axis in
pancreatic cancer. Clin Cancer Res. 22:3950–3960. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liang C, Qin Y, Zhang B, Ji S, Shi S, Xu
W, Liu J, Xiang J, Liang D, Hu Q, et al: Oncogenic KRAS targets
MUC16/CA125 in pancreatic ductal adenocarcinoma. Mol Cancer Res.
15:201–212. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Maréchal R, Bachet JB, Mackey JR, Dalban
C, Demetter P, Graham K, Couvelard A, Svrcek M, Bardier-Dupas A,
Hammel P, et al: Levels of gemcitabine transport and metabolism
proteins predict survival times of patients treated with
gemcitabine for pancreatic adenocarcinoma. Gastroenterology.
143:664–674. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nordh S, Ansari D and Andersson R: hENT1
expression is predictive of gemcitabine outcome in pancreatic
cancer: A systematic review. World J Gastroenterol. 20:8482–8490.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Spratlin J, Sangha R, Glubrecht D, Dabbagh
L, Young JD, Dumontet C, Cass C, Lai R and Mackey JR: The absence
of human equilibrative nucleoside transporter 1 is associated with
reduced survival in patients with gemcitabine-treated pancreas
adenocarcinoma. Clin Cancer Res. 10:6956–6961. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Plunkett W, Huang P, Searcy CE and Gandhi
V: Gemcitabine: Preclinical pharmacology and mechanisms of action.
Semin Oncol. 23 Suppl 10:S3–S15. 1996.
|
|
18
|
Kourie HR, Gharios J, Elkarak F, Antoun J
and Ghosn M: Is metastatic pancreatic cancer an untargetable
malignancy? World J Gastrointest Oncol. 8:297–304. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ertel F, Nguyen M, Roulston A and Shore
GC: Programming cancer cells for high expression levels of Mcl1.
EMBO Rep. 14:328–336. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wertz IE, Kusam S, Lam C, Okamoto T,
Sandoval W, Anderson DJ, Helgason E, Ernst JA, Eby M, Liu J, et al:
Sensitivity to antitubulin chemotherapeutics is regulated by MCL1
and FBW7. Nature. 471:110–114. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lucchetti C, Rizzolio F, Castronovo M and
Toffoli G: Research highlights. MCL1 and FBW7 as new predictive
candidate biomarkers of anti-tubulin agents. Pharmacogenomics.
12:1379–1380. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kirkegaard T and Jäättelä M: Lysosomal
involvement in cell death and cancer. Biochim Biophys Acta.
1793:746–754. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Guicciardi ME, Leist M and Gores GJ:
Lysosomes in cell death. Oncogene. 23:2881–2890. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Maxfield FR and McGraw TE: Endocytic
recycling. Nat Rev Mol Cell Biol. 5:121–132. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Seixas E, Barros M, Seabra MC and Barral
DC: Rab and Arf proteins in genetic diseases. Traffic. 14:871–885.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
D'Souza-Schorey C and Chavrier P: ARF
proteins: Roles in membrane traffic and beyond. Nat Rev Mol Cell
Biol. 7:347–358. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Le Roy C and Wrana JL: Clathrin- and
non-clathrin-mediated endocytic regulation of cell signalling. Nat
Rev Mol Cell Biol. 6:112–126. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rainero E: Extracellular matrix
endocytosis in controlling matrix turnover and beyond: Emerging
roles in cancer. Biochem Soc Trans. 44:1347–1354. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
White E, Mehnert JM and Chan CS:
Autophagy, metabolism, and cancer. Clin Cancer Res. 21:5037–5046.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Peng K, Dai Q, Wei J, Shao G, Sun A, Yang
W and Lin Q: Stress-induced endocytosis and degradation of
epidermal growth factor receptor are two independent processes.
Cancer Cell Int. 16:252016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sorkin A: Internalization of the epidermal
growth factor receptor: Role in signalling. Biochem Soc Trans.
29:480–484. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Joffre C, Barrow R, Ménard L, Calleja V,
Hart IR and Kermorgant S: A direct role for Met endocytosis in
tumorigenesis. Nat Cell Biol. 13:827–837. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Seton-Rogers S: Signalling: Location,
location, location. Nat Rev Cancer. 11:462–463. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Clague MJ: Met receptor: A moving target.
Sci Signal. 4:pe402011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mosesson Y, Mills GB and Yarden Y:
Derailed endocytosis: An emerging feature of cancer. Nat Rev
Cancer. 8:835–850. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tardy C, Codogno P, Autefage H, Levade T
and Andrieu-Abadie N: Lysosomes and lysosomal proteins in cancer
cell death (new players of an old struggle). Biochim Biophys Acta.
1765:101–125. 2006.PubMed/NCBI
|
|
37
|
Appelqvist H, Wäster P, Kågedal K and
Öllinger K: The lysosome: From waste bag to potential therapeutic
target. J Mol Cell Biol. 5:214–226. 2013. View Article : Google Scholar : PubMed/NCBI
|
